“Why Do I Believe This $1.55 Medical Technology Stock Will Break $20?”

That’s the headline of a very brief teaser that’s been circulating from Andy Obermueller, one of the StreetAuthority newsletter editors — he started out with the Government-Driven Investing newsletter about a year ago, a letter that brought us plenty of interesting teasers, and also apparently edits Fast-Track Millionaire, a new service that they’re launching soon to focus on “innovative technologies and ‘game-changing’ trends.”

And in order to get folks excited about this new service, they’re having a special “free webcast event” next week, on June 15 — an event at which Obermueller will apparently talk about four of his favorite high-octane stocks. I have no idea how much information they’ll actually give away for free (assuming you consider an investment of your time to listen, and your information on a registration form, is “free”), but I do know that today is not June 15 … and I want to know the stocks he’s thinking about now.

Unfortunately, the very short ad only teases one of his investment ideas — but still, one is better than nothing, right? I don’t know if his idea will be a great one, but he did tease at least one great performer in the past (Dyadic International, the fungus company — he teased this as the “next Budweiser or next Exxon” last July and it’s up from about 40 cents to $2+) … they haven’t all been winners, other picks of his that we’ve sniffed out have been the ethanol play Verenium (just about flat), and desalination plant part-maker Energy Recovery (down substantially — so of course, this is the one that I happen to own shares of).

But still … the clues are out, and your friendly neighborhood Gumshoe can’t help it, I want to follow the clues to the end of the rainbow. So what’s the tease?

“How would you like to make some serious money while helping 50,000 people beat a killer disease?

“I’ve discovered a company that is about to take a huge step forward against America’s #2 cause of cancer death — colon cancer — while reaping a windfall of profits in the process. Early investors who get in on this opportunity could be making money hand-over-fist.

“Colon cancer is serious matter. About 50,000 people die from it each year. There is a test for it, but it is so unpleasant that only half the people who should get tested actually do.

“Thanks to this company, there is now a more pleasant alternative: a virtual colonoscopy. This machine scans your colon from the outside. It’s fast, accurate and pain-free. This company is on the verge of getting FDA approval for their virtual colonoscopy tool and I see this as an opportunity that is about to pop. ”

So … not a lot of clues, right? Virtual colonoscopy, priced around $1.55, “on the verge” of getting FDA approval. Throw that data into the mighty, mighty Thinkolator and we find that this must be:

iCAD, Inc. (ICAD — click here for the free instant analysis of ICAD from Marketclub, one of my advertising partners)

This is indeed a computerized imagine company that works on cancer detection, so far it looks like their virtual scans are primarily used for mammographies, for which their system has been approved for about eight years. They don’t actually make the devices, as far as I can tell — they’re not building and selling the x-ray machines, MRIs or other tools, they apparently improve those tools with advanced image processing software and “workflow solutions.”

And yes, they have been awaiting the approval of their VeraLook system from the FDA, a system that is indeed already being used in Europe. Here’s how they sell it on the website:

“VeraLook* from iCAD uses sophisticated image processing software to automatically identify polyps in CTC images. Working in conjunction with state-of-the art hardware and image visualization software from partners that include Viatronix, Tera Recon and Vital Images, our solution highlights polyp locations to the interpreting physician. iCAD’s VeraLook can:

* Identify colon polyps to aid in the reading process
* Integrate with specialized CTC reading environments
* Improve accuracy, productivity and workflow
* Streamline the reading process and improve consistency”

And to be clear, you CAN get a virtual colonoscopy in the US today, you just can’t get one